Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome

Lipids

Volumn 44, Issue 1, 2009, Pages 9-16

  Lagos, K G ^a   Filippatos, T D ^b   Tsimihodimos, V ^a   Gazi, I F ^a   Rizos, C ^a   Tselepis, A D ^c   Mikhailidis, D P ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

High density lipoprotein; High sensitivity C reactive protein; Lipoprotein associated phospholipase A2; Metabolic syndrome; Paraoxonase 1; Small dense low density lipoprotein cholesterol; Subclasses; Triglycerides

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE;

EID: 57849164937     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-008-3251-9     Document Type: Article

References (51)

1. RH Eckel SM Grundy PZ Zimmet 2005 The metabolic syndrome Lancet 365 1415 1428
2. SS Daskalopoulou DP Mikhailidis M Elisaf 2004 Prevention and treatment of the metabolic syndrome Angiology 55 589 612
3. HM Lakka DE Laaksonen TA Lakka LK Niskanen 2002 The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2709 2716
4. I Gazi V Tsimihodimos T Filippatos E Bairaktari AD Tselepis M Elisaf 2006 Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria Metabolism 55 885 891
5. MJ Chapman G Assmann JC Fruchart J Shepherd C Sirtori 2004 Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C Curr Med Res Opin 20 1253 1268
6. A Kontush MJ Chapman 2006 Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3 144 153
7. BF Asztalos LA Cupples S Demissie KV Horvath 2004 High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study Arterioscler Thromb Vasc Biol 24 2181 2187
8. JT Salonen R Salonen K Seppanen R Rauramaa J Tuomilehto 1991 HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men Circulation 84 129 139
9. JJ Link A Rohatgi JA de Lemos 2007 HDL cholesterol: physiology, pathophysiology, and management Curr Probl Cardiol 32 268 314
10. M Florentin EN Liberopoulos AS Wierzbicki DP Mikhailidis 2008 Multiple actions of high-density lipoprotein Curr Opin Cardiol 23 370 378
11. AD Tselepis JM Chapman 2002 Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase Atheroscler Suppl 3 57 68
12. RW James 2006 A long and winding road: defining the biological role and clinical importance of paraoxonases Clin Chem Lab Med 44 1052 1059
13. SM Grundy JI Cleeman CN Merz HB Brewer Jr 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines J Am Coll Cardiol 44 720 732
14. ET Bairaktari KI Seferiadis MS Elisaf 2005 Evaluation of methods for the measurement of low-density lipoprotein cholesterol J Cardiovasc Pharmacol Ther 10 45 54
15. VG Saougos AP Tambaki M Kalogirou M Kostapanos 2007 Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2236 2243
16. TD Filippatos EN Liberopoulos M Kostapanos IF Gazi 2008 The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome Diabetes Obes Metab 10 476 483
17. I Gazi ES Lourida T Filippatos V Tsimihodimos M Elisaf AD Tselepis 2005 Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma Clin Chem 51 2264 2273
18. TD Filippatos IF Gazi EN Liberopoulos VG Athyros 2007 The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome Atherosclerosis 193 428 437
19. AD Tselepis C Dentan SA Karabina MJ Chapman E Ninio 1995 PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme Arterioscler Thromb Vasc Biol 15 1764 1773
20. V Tsimihodimos SA Karabina AP Tambaki E Bairaktari 2002 Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB Arterioscler Thromb Vasc Biol 22 306 311
21. A von Eckardstein JR Nofer G Assmann 2001 High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport Arterioscler Thromb Vasc Biol 21 13 27
22. SS Deeb A Zambon MC Carr AF Ayyobi JD Brunzell 2003 Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet J Lipid Res 44 1279 1286
23. S Kathiresan JD Otvos LM Sullivan MJ Keyes 2006 Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 20 29
24. JA de Souza C Vindis B Hansel A Negre-Salvayre 2008 Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity Atherosclerosis 197 84 94
25. J Ji GF Watts AG Johnson DC Chan 2006 High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics J Clin Endocrinol Metab 91 973 979
26. BF Asztalos D Collins LA Cupples S Demissie 2005 Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial Arterioscler Thromb Vasc Biol 25 2185 2191
27. BF Asztalos M Batista KV Horvath CE Cox 2003 Change in alpha1 HDL concentration predicts progression in coronary artery stenosis Arterioscler Thromb Vasc Biol 23 847 852
28. JD Otvos D Collins DS Freedman I Shalaurova 2006 Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 113 1556 1563
29. VG Athyros AI Kakafika A Karagiannis DP Mikhailidis 2008 Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 200 1 12
30. M Elisaf AD Tselepis 2003 Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis Biochem Pharmacol 66 2069 2073
31. B Hansel A Kontush D Bonnefont-Rousselot E Bruckert MJ Chapman 2006 Alterations in lipoprotein defence against oxidative stress in metabolic syndrome Curr Atheroscler Rep 8 501 509
32. B Hansel P Giral E Nobecourt S Chantepie 2004 Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity J Clin Endocrinol Metab 89 4963 4971
33. E Rizos AP Tambaki I Gazi AD Tselepis M Elisaf 2005 Lipoprotein- associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome Prostaglandins Leukot Essent Fatty Acids 72 203 209
34. MI Mackness B Mackness PN Durrington PW Connelly RA Hegele 1996 Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins Curr Opin Lipidol 7 69 76
35. MI Mackness PN Durrington 1995 HDL, its enzymes and its potential to influence lipid peroxidation Atherosclerosis 115 243 253
36. MI Mackness B Mackness PN Durrington 2002 Paraoxonase and coronary heart disease Atheroscler Suppl 3 49 55
37. MI Mackness S Arrol C Abbott PN Durrington 1993 Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis 104 129 135
38. MC Garin B Kalix A Morabia RW James 2005 Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome J Clin Endocrinol Metab 90 2264 2269
39. E Moldoveanu C Tanaseanu S Tanaseanu T Kosaka 2006 Plasma markers of endothelial dysfunction in type 2 diabetics Eur J Intern Med 17 38 42
40. MI Mackness D Harty D Bhatnagar PH Winocour 1991 Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus Atherosclerosis 86 193 199
41. B Mackness PN Durrington B Abuashia AJ Boulton MI Mackness 2000 Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy Clin Sci (Lond) 98 355 363
42. FD Brites J Verona LE Schreier JC Fruchart GR Castro RL Wikinski 2004 Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low HDL-cholesterol levels with or without primary hypertriglyceridemia Arch Med Res 35 235 240
43. E Nobecourt S Jacqueminet B Hansel S Chantepie 2005 Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia Diabetologia 48 529 538
44. T Kalmar I Seres Z Balogh M Kaplar G Winkler G Paragh 2005 Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus Diabetes Metab 31 574 580
45. CC Hedrick SR Thorpe MX Fu CM Harper 2000 Glycation impairs high-density lipoprotein function Diabetologia 43 312 320
46. J Rysz R Blaszczak M Banach K Kedziora-Kornatowska 2007 Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation Arch Immunol Ther Exp (Warsz) 55 335 340
47. M Persson B Hedblad JJ Nelson G Berglund 2007 Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects Arterioscler Thromb Vasc Biol 27 1411 1416
48. J Saltevo M Vanhala H Kautiainen E Kumpusalo M Laakso 2007 Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome Mediators Inflamm. 2007 93573
49. HJ Milionis E Rizos J Goudevenos K Seferiadis DP Mikhailidis MS Elisaf 2005 Components of the metabolic syndrome and risk for first-ever acute ischemic non-embolic stroke in elderly subjects Stroke 36 1372 1376
50. IF Gazi V Tsimihodimos AD Tselepis M Elisaf DP Mikhailidis 2007 Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles Expert Opin Biol Ther 7 53 72
51. T Filippatos V Tsimihodimos M Kostapanos C Kostara 2008 Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome Arch Med Sci 4 263 269